TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2909317
Drug: 0.1 mg/kg.h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg.h
Study: 2909317
Drug: 0.2 mg/kg.h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg.h
Study: 30099833
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid solution (Transamin inj/sol 500 mg/5 mL) infused wet dressing for 20 minutes
Study: 30099833
Drug: Microneedling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling with tranexamic acid solution topical application followed by tranexamic acid solution infused dressing therapy every 15 days for four sessions
Study: 23477572
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy and radiation therapy (ADT‐RTH)
Study: 23477572
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy only (RTH)
Study: 21684281
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg LX1031, given 4 times/day
Study: 21684281
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg LX1031, given 4 times/day
Study: 11295717
Drug: RORS-G (glucose-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: RORS-G (glucose-based reduced osmolarity ORS)
Study: 9229021
Drug: Ivermectin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150 micrograms/kg body weight) on day 1 followed by amocarzine (3 mg/kg twice daily after meals) on days 8, 9, and 10
Study: 23449426
Drug: Allopurinol 600
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 600 mg/day for 9 months
Study: 16818810
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (control group)
Study: 12507797
Drug: Mandatory drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory drug testing (DT)
Study: 12507797
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) - No mandatory drug testing
Study: 3282670
Drug: Flunarizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (5 mg/day)
Study: 12946491
Drug: Topical methylprednisolone
Normalized name: methylprednisolone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methylprednisolone (80 mg)
Study: 12946491
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 5% (15 puffs)
Study: 15017487
Drug: Once-daily mesalamine
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-daily mesalamine (QD)
Study: 15017487
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing mesalamine (CD)
Study: 9925862
Drug: rHuEPO in
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO in non-CDDP chemotherapy regimens
Study: 8800821
Drug: Naloxone at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone at 10% or less of the 24 h dose of morphine (placebo controlled)
Study: 8800821
Drug: Naloxone at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone at 20% of the 24 h dose of morphine
Study: 8800821
Drug: Naloxone at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone at maximum doses of 20%, 40%, and 80% of the 24 h dose of morphine
Study: 1386766
Drug: Ketoconazole 2%
Normalized name: KETOCONAZOLE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 2% foaming gel
Study: 1386766
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate 0.05% lotion
Study: 28954455
Drug: Sibelium in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibelium in combination with dibazole
Study: 21461638
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (20 U [0.2 ml])
Study: 21461638
Drug: Placebo (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.2 ml)
Study: 15545047
Drug: Meat products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat products enriched with plant sterols (1.2 g/day), potassium, calcium and magnesium (MP1)
Study: 15545047
Drug: Meat products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat products with plant sterols (2.1 g/day), potassium, calcium and magnesium (MP2)
Study: 11545671
Drug: Collaborative Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative Care (CC) - educational videotapes and pamphlets; pharmacotherapy with paroxetine; 2 psychiatrist visits and 2 telephone calls in the first 8 weeks; up to 5 telephone calls between 3 and 12 months' follow-up
Study: 8494706
Drug: MPA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA (100 mg tds orally)
Study: 3480298
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without teflon membrane
Study: 29780236
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of fimasartan (60 mg), amlodipine (10 mg), and rosuvastatin (20 mg) administered once
Study: 29780236
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of fimasartan (60 mg), amlodipine (10 mg), and rosuvastatin (20 mg) administered twice
Study: 29780236
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (FDC and co-administration)
Study: 25967606
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (1.5-g daily)
Study: 22562983
Drug: MTX+TCZ (tocilizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX+TCZ (tocilizumab 8 mg/kg every 4 weeks)
Study: 21968126
Drug: prediction based
Approvals — FDA: no, EMA: no, PMDA: no
Description: prediction based treatment
Study: 16792053
Drug: Sonic scaler
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonic scaler (Sonicflex 2003 L, KaVo)
Study: 8370428
Drug: UK‐38,485 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK‐38,485 (600 mg daily)
Study: 28027333
Drug: Quarterly updated
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarterly updated personalized antibiotic prescription feedback over 2 years (n=1450)
Study: 25893955
Drug: Combined inhibition
Normalized name: ACE INHIBITORS, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined inhibition of nitric oxide (NO) and prostaglandin (PG) synthesis (l-NMMA + ketorolac)
Study: 25893955
Drug: Combined KIR
Normalized name: Trichosanthes kirilowii fruit rind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined KIR channel and Na(+) /K(+) -ATPase inhibition (l-NMMA + ketorolac + BaCl2 + ouabain)
Study: 21563505
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine for 12 weeks
Study: 21563505
Drug: Loxoprofen Sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen Sodium Tablet and Leifumite Tablet for 12 weeks
Study: 19571082
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human bone morphogenetic protein-2 (rhBMP-2) on an absorbable collagen sponge with ceramic granules; total dose of rhBMP-2, 12 mg.
Study: 15478678
Drug: EMG-guided BOTOX
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG-guided BOTOX injection
Study: 15478678
Drug: Non EMG-guided
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non EMG-guided BOTOX injection
Study: 11012480
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg o.d. + Levofloxacin 500 mg o.d. + Amoxycillin 1 g b.d. (RLA group)
Study: 11012480
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg o.d. + Levofloxacin 500 mg o.d. + Tinidazole 500 mg b.d. (RLT group)
Study: 9330929
Drug: HCQ 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ 400 mg/day (n = 41)
Study: 8452164
Drug: Fleroxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin, 400 mg once daily
Study: 8452164
Drug: Norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 400 mg twice daily
Study: 2429466
Drug: Flecainide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (2 X 200 mg)
Study: 2429466
Drug: Prajmalium-bitartrate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prajmalium-bitartrate (4 X 20 mg)
Study: 30053196
Drug: 6-week self-administered
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week self-administered cognitive-behavioral therapy for insomnia (CBT-I)
Study: 25041791
Drug: Cixutumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (6 mg/kg/week intravenously), Erlotinib (100 mg/day orally), Gemcitabine (1000 mg/m2 intravenously on days 1, 8, and 15 of a 28-day cycle)
Study: 22327716
Drug: Intraventricular thrombolysis
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular thrombolysis with rt-PA (Actilyse(®)) 5 mg every 12 h and lateral rotational therapy (RotoRest(®))
Study: 12125943
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate ointment (Diprosone)
Study: 12125943
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (Daivonex)
Study: 12125943
Drug: Combination ointment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ointment vs Betamethasone
Study: 12125943
Drug: Combination ointment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ointment vs Calcipotriol
Study: 12125943
Drug: Combination ointment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ointment
Study: 10594518
Drug: Continuous GHRH(1-29)NH2
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous GHRH(1-29)NH2 (60 ng/kg/min, subcutaneous infusion, 24 h)
Study: 10594518
Drug: Intermittent SS(1-14)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent SS(1-14) withdrawal (20 microg/m2/hour, intravenous infusion, 3 h on/1 h off, 2-3 cycles over 8-12 h)
Study: 2072886
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral supplementation with folic acid before conception and during early pregnancy
Study: 30950711
Drug: Rezum® System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezum® System thermal therapy
Study: 19474141
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (18 g) + isoflavone tablets (105 mg isoflavone aglycone equivalents)
Study: 19474141
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein + placebo tablets
Study: 19474141
Drug: Control protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control protein + isoflavone tablets
Study: 19474141
Drug: Control protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control protein + placebo tablets
Study: 15551252
Drug: Levofloxacin-based regimen
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based regimen (pantoprazole 40 mg, amoxicillin 1 g, levofloxacin 250 mg, all twice daily for 10 days)
Study: 15551252
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (omeprazole 20 mg twice daily for the first week, then omeprazole 20 mg twice daily, tetracycline 250 mg 4 times daily, metronidazole 500 mg twice daily, and bismuth subcitrate 240 mg twice daily for the second week)
Study: 7711420
Drug: MFP‐Ca (13.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP‐Ca (13.2 mg fluoride) twice a day
Study: 7711420
Drug: NaF (11.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF (11.3 mg fluoride) twice a day
Study: 24492839
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E supplementation (1000 mg of vitamin C and 235 mg of vitamin E daily for 11 weeks)
Study: 15805990
Drug: ICS therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS therapy based on changes in sputum eosinophil counts
Study: 1499250
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine rinse, 15 ml solution, twice daily for 30 seconds
Study: 6092011
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose prophylaxis with cefotaxime
Study: 6092011
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose prophylaxis with cefotaxime for 24 hours
Study: 29624800
Drug: Degarelix (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (240 mg initial dose, 480 mg maintenance every 84 days)
Study: 29624800
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg initial dose, 10.8 mg maintenance every 84 days)
Study: 23851424
Drug: L-carnitine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine infusion
Study: 15793394
Drug: KTP laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP laser treatment during staged intact canal wall surgery
Study: 15793394
Drug: No KTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No KTP laser treatment during staged intact canal wall surgery
Study: 11952445
Drug: Rectally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectally administered diclofenac (Voltaren) 1 mg/kg
Study: 11952445
Drug: i.v. opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. opioid (morphine) 0.05 mg/kg
Study: 9443925
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of alendronate daily
Study: 7639416
Drug: Ibudilast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (10 mg)
Study: 2236462
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for children with pure depression or depression plus an anxiety-related disorder
Study: 2236462
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for children with pure depression or depression plus an anxiety-related disorder
Study: 2236462
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for children with depression plus a concomitant conduct or oppositional disorder
Study: 2236462
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for children with depression plus a concomitant conduct or oppositional disorder
Study: 31821071
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose tamoxifen (ID arm; 40 mg daily)
Study: 31821071
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose tamoxifen (RD arm; 20 mg daily)
Study: 31821071
Drug: Homozygous wild-type
Normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homozygous wild-type (wt/wt) patients (20 mg daily)
Study: 21558066
Drug: Magnesium (5
Normalized name: magnesium gluconate 30 mg magnesium (550 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (5 g daily) administered intraoperatively and on days 1 and 2 after operation
Study: 21558066
Drug: Magnesium (5
Normalized name: magnesium gluconate 30 mg magnesium (550 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (5 g daily) in patients undergoing pneumonectomy
Study: 18823363
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment from the start without detoxification
Study: 18823363
Drug: Standard out-patient
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard out-patient detoxification programme without prophylactic treatment from the start
Study: 18823363
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific treatment (5-month follow-up)
Study: 30088452
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy plus knockdown or mimicking microRNA
Study: 30088452
Drug: Antagonist oligonucleotides
Normalized name: Exon 53 specific antisense morpholino oligonucleotide
DrugBank: Viltolarsen (DB15005)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antagonist oligonucleotides like antagomiRs or anti-miRs and microRNA mimicking
Study: 26686359
Drug: Onion juice
Normalized name: ONION JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion juice (100 mL daily for 8 weeks)
Study: 22549092
Drug: Basiliximab 20
Normalized name: basiliximab 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab 20 mg
Study: 22549092
Drug: Basiliximab 40
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab 40 mg
Study: 20569714
Drug: Optimal evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal evidence-based medical therapy (use of all 4 indicated medications)
Study: 20569714
Drug: Optimal evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal evidence-based medical therapy
Study: 18390443
Drug: Quibron SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quibron SR tablets 300 mg
Study: 18390443
Drug: Respro-SR pellets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respro-SR pellets filled Capsules 300 mg
Study: 16206579
Drug: Preventive load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive load and early administration of antioxidants (Group 2), enterally fed with Berlamine-modular for 5 days before surgery and in the postoperative period.
Study: 16206579
Drug: High oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oxygen supply values at all stages of surgical treatment (Group 3), optimized infusion therapy and compensated intraoperative blood loss.
Study: 10594520
Drug: Insulin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.15 units/kg, iv) induced hypoglycaemia
Study: 10594520
Drug: GHRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (100 mg, iv) with and without pyridostigmine (120 mg orally)
Study: 2328558
Drug: Analgesic agent
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic agent
Study: 2328558
Drug: Analgesic plus
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic plus antihistaminic agent
Study: 23527358
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed with adequate primary stability
Study: 23527358
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in residual bone crests greater than 2 mm but less than 4 mm
Study: 21851642
Drug: Fixed-combination latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-combination latanoprost 50 μg/mL and timolol 0.5 mg/mL (LTFC)
Study: 21851642
Drug: Unfixed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfixed combination of latanoprost (one drop in the evening) and timolol (one drop in the morning) (LTuFC)
Study: 15669455
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia (20 ml of 2% lidocaine with adrenaline 1 in 200000)
Study: 15669455
Drug: Combined 3-in-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 3-in-1 and sciatic nerve block (50 ml of 1% lignocaine with adrenaline 1 in 200000, using nerve stimulator)
Study: 11463596
Drug: Nasal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal continuous positive airway pressure (CPAP) treatment for 6 months
Study: 31861028
Drug: Ibuprofen (n=20)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (n=20)
Study: 31861028
Drug: Paracetamol (n=20)
Normalized name: tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (n=20)
Study: 30019653
Drug: Polysialylated erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysialylated erythropoietin (PSA‐EPO), administered subcutaneously, aimed for once monthly administration.
Study: 30019653
Drug: Polysialylated deoxyribonuclease
Normalized name: deoxyribonucleases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysialylated deoxyribonuclease I (PSA‐DNase), details on administration not specified.
Study: 12424547
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg caffeine (at breakfast)
Study: 12424547
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg caffeine (at breakfast)
Study: 12424547
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg caffeine (60 min after breakfast)
Study: 12424547
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg caffeine (after breakfast)
Study: 10051499
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of recombinant vaccine (group 1)
Study: 10051499
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of recombinant vaccine (group 2)